Spectrum Pharmaceuticals Given Consensus Rating of “Hold” by Brokerages (NASDAQ:SPPI)
Spectrum Pharmaceuticals (NASDAQ:SPPI) has received an average rating of “Hold” from the nine ratings firms that are currently covering the stock, AnalystRatings.Net reports. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $11.93.
Shares of Spectrum Pharmaceuticals (NASDAQ:SPPI) traded up 2.20% during mid-day trading on Tuesday, hitting $7.43. 211,053 shares of the company’s stock traded hands. Spectrum Pharmaceuticals has a 52 week low of $6.95 and a 52 week high of $10.32. The stock has a 50-day moving average of $8.09 and a 200-day moving average of $8.63. The company’s market cap is $468.8 million.
Spectrum Pharmaceuticals (NASDAQ:SPPI) last announced its earnings results on Thursday, March 6th. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.16. The company had revenue of $41.50 million for the quarter, compared to the consensus estimate of $41.96 million. The company’s revenue for the quarter was down 40.7% on a year-over-year basis. Analysts expect that Spectrum Pharmaceuticals will post $-0.54 EPS for the current fiscal year.
A number of research firms have recently commented on SPPI. Analysts at TheStreet downgraded shares of Spectrum Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday. Analysts at Roth Capital reiterated a “buy” rating on shares of Spectrum Pharmaceuticals in a research note on Thursday, February 6th.
Spectrum Pharmaceuticals, Inc (NASDAQ:SPPI) is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.